TY - JOUR
T1 - From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
AU - Palumbo, Giuseppe A.
AU - Galimberti, Sara
AU - Barcellini, Wilma
AU - Cilloni, Daniela
AU - Di Renzo, Nicola
AU - Elli, Elena Maria
AU - Finelli, Carlo
AU - Maurillo, Luca
AU - Ricco, Alessandra
AU - Musto, Pellegrino
AU - Russo, Rodolfo
AU - Latagliata, Roberto
N1 - Funding Information:
Medical writing assistance for the preparation of this article was funded by Novartis Pharma, Italy. The funder was not involved in the writing of this article or the decision to submit it for publication.
Publisher Copyright:
© Copyright © 2021 Palumbo, Galimberti, Barcellini, Cilloni, Di Renzo, Elli, Finelli, Maurillo, Ricco, Musto, Russo and Latagliata.
PY - 2021/10/6
Y1 - 2021/10/6
N2 - Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, with the aim to reduce iron overload (IOL) and prevent organ damage. This therapeutic approach is already widely used in thalassemic patients and in low-risk Myelodysplastic Syndrome (MDS) patients. More recently, ICT has been proposed for high-risk MDS, especially when an allogeneic bone marrow transplantation has been planned. Furthermore, other hematological and hereditary disorders, characterized by considerable transfusion support to manage anemia, could benefit from this therapy. Meanwhile, data accumulated on how iron toxicity could exacerbate anemia and other clinical comorbidities due to oxidative stress radical oxygen species (ROS) mediated by free iron species. Taking all into consideration, together with the availability of approved oral iron chelators, we envision a larger use of ICT in the near future. The aim of this review is to better identify those non-thalassemic patients who can benefit from ICT and give practical tips for management of this therapeutic strategy.
AB - Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, with the aim to reduce iron overload (IOL) and prevent organ damage. This therapeutic approach is already widely used in thalassemic patients and in low-risk Myelodysplastic Syndrome (MDS) patients. More recently, ICT has been proposed for high-risk MDS, especially when an allogeneic bone marrow transplantation has been planned. Furthermore, other hematological and hereditary disorders, characterized by considerable transfusion support to manage anemia, could benefit from this therapy. Meanwhile, data accumulated on how iron toxicity could exacerbate anemia and other clinical comorbidities due to oxidative stress radical oxygen species (ROS) mediated by free iron species. Taking all into consideration, together with the availability of approved oral iron chelators, we envision a larger use of ICT in the near future. The aim of this review is to better identify those non-thalassemic patients who can benefit from ICT and give practical tips for management of this therapeutic strategy.
KW - anemia
KW - deferasirox
KW - iron chelation therapy (ICT)
KW - iron toxicity
KW - myelodysplastic syndromes (MDS)
KW - myelofibrosis (MF)
KW - radical oxygen species (ROS)
UR - http://www.scopus.com/inward/record.url?scp=85117505627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117505627&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.752192
DO - 10.3389/fonc.2021.752192
M3 - Review article
AN - SCOPUS:85117505627
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 752192
ER -